Elon Musk bungles his criticism of U.S. drug regulators

Taking stock of the drug industry, from the lab to the medicine chest

October 24, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Michael Swensen/Getty Images STAT+ | Elon Musk bungles his criticism of U.S. drug regulators In a twist on Musk's familiar lament about government regulation, he cited the FDA and a Merck cancer drug called Welireg. By Adam Feuerstein STAT+ | Ozempic linked to lower risk of Alzheimer's diagnosis in observational study In the observational study, the drug was tied with a 40% to 70% lower risk of an Alzheimer's diagnosis over three years compared with other diabetes drugs. By Elaine Chen STAT+ | Gilead needs a win with Arcellx CAR-T data. Here's how to know if it scores Anito-cel has multibillion-dollar sales potential, if it proves to be competitive on efficacy and safer from a neurotoxicity perspective than Carvykti. By Adam Feuerstein Brynn Anderson/AP How a Kamala Harris presidency would change health care, from drug pricing to abortion New Medicare benefit for home care, drug pricing changes, surprise billing protections, and codifying abortion access all require action from lawmakers. By Rachel Cohrs Zhang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser